Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats

Vascular Pharmacology

Volumn 40, Issue 5, 2003, Pages 253-259

  Elmarakby, Ahmed A ^a   Morsing, Peter ^b   Pollock, Jennifer S ^a   Pollock, David M ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Second Swed Natl Pension Fund AP2   (Sweden)

Author keywords

Angiotensin converting enzyme inhibitors; DOCA salt rats; Urinary endothelin excretion; Vasopeptidase inhibitors

Indexed keywords

ACETIC ACID; DEOXYCORTICOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN; OMAPATRILAT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG URINE LEVEL; EXPERIMENTAL MODEL; HYPERTENSION; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TELEMETRY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; DESOXYCORTICOSTERONE; DRINKING; EATING; ENALAPRILAT; ENDOTHELINS; HYPERTENSION; KIDNEY; MALE; PROTEASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; SODIUM; THIAZEPINES;

EID: 1642503706     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2004.01.002     Document Type: Article

References (27)

1. A receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats. Am. J. Physiol. 275:1998;R245-R252.
2. Burnett J.C. Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertens., Suppl. 17:1999;S37-S43.
3. Ergul S., Ergul A., Hudson J.A., Puett D., Wieman B.M., Durham M.D., Parish D.C. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am. J. Hypertens. 11:1998;1381-1385.
4. Grantham J.A., Schirger J.A., Wennberg P.W., Sandberg S., Heublein D.M., Subkowski T., Burnett J.C. Jr. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. Circulation. 101:2000;1976-1981.
5. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem. J. 291:1993;83-88.
6. Lariviere R., Day R., Schiffrin E.L. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 21:1993;916-920.
7. Lariviere R., Thibault G., Schiffrin E.L. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 21:1993;294-300.
8. A receptor antagonist on renal function of DOCA-salt hypertensive rats. Eur. J. Pharmacol. 319:1997;65-69.
9. McDowell G., Coutie W., Shaw C., Buchanan K.D., Struthers A.D., Nicholls D.P. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br. J. Clin. Pharmacol. 43:1997;329-332.
10. Murphy L.J., Corder R., Mallet A.I., Turner A.J. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br. J. Pharmacol. 113:1994;137-142.
11. Newaz M.A., Yousefipour Z., Hercule H., Truong L., Oyekan A. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection. Clin. Exp. Hypertens. 25:2003;335-347.
12. Oyekan A.O., McAward K., Conetta J., Rosenfeld L., McGiff J.C. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am. J. Physiol. 276:1999;R766-R775.
13. Pollock D.M. Renal endothelin in hypertension. Curr. Opin. Nephrol. Hypertens. 9:2000;157-164.
14. Pollock D.M., Pollock J.S. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol., Renal. Physiol. 281:2001;F144-F150.
15. Pollock D.M., Rekito A. Hypertensive response to chronic NO synthase inhibition is different in Sprague-Dawley rats from two suppliers. Am. J. Physiol. 275:1998;R1719-R1723.
16. Pollock J.S., Forstermann U., Mitchell J.A., Warner T.D., Schmidt H.H., Nakane M., Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 88:1991;10480-10484.
17. Pu Q., Touyz R.M., Schiffrin E.L. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J. Hypertens. 20:2002;899-907.
18. Quaschning T., Galle J., Wanner C. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction. Kidney Int., Suppl. 2003;S54-S57.
19. Robl J.A., Sun C.Q., Stevenson J., Ryono D.E., Simpkins L.M., Cimarusti M.P., Dejneka T., Slusarchyk W.A., Chao S., Stratton L., Misra R.N., Bednarz M.S., Asaad M.M., Cheung H.S., Abboa-Offei B.E., Smith P.L., Mathers P.D., Fox M., Schaeffer T.R., Seymour A.A., Trippodo N.C. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J. Med. Chem. 40:1997;1570-1577.
20. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br. J. Pharmacol. 121:1997;935-940.
21. Taylor T.A., Pollock J.S., Pollock D.M. Down-regulation of soluble guanylyl cyclase in the inner medulla of DOCA-salt hypertensive rats. Vasc. Pharmacol. 40:2003;155-160.
22. Treiber F.A., Jackson R.W., Davis H., Pollock J.S., Kapuku G., Mensah G.A., Pollock D.M. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension. 35:2000;722-725.
23. Trippodo N.C., Robl J.A., Asaad M.M., Bird J.E., Panchal B.C., Schaeffer T.R., Fox M., Giancarli M.R., Cheung H.S. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J. Pharmacol. Exp. Ther. 275:1995;745-752.
24. Trippodo N.C., Robl J.A., Asaad M.M., Fox M., Panchal B.C., Schaeffer T.R. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am. J. Hypertens. 11:1998;363-372.
25. B receptors in the renal medulla. Hypertension. 41:2003;1359-1363.
26. Weber M.A. Vasopeptidase inhibitors. Lancet. 358:2001;1525-1532.
27. Zanchi A., Maillard M., Burnier M. Recent clinical trials with omapatrilat: new developments. Curr. Hypertens. Rep. 5:2003;346-352.